Importantly, activation of tyrosine kinases including LYN, FYN, and AXL has been reported in IM and Nilotinib-resistant cell lines and also in some CML patients treated with such inhibitors [9-11]. Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.